Contrast Media Agent Market Is Witnessing Significant Growth Due To Increasing Prevalence Of Long-Term Diseases & Complex Comorbidities Till 2025


The global contrast media agents market size is estimated to reach USD 5.96 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 3.8% during the forecast period. Increasing burden of chronic diseases is augmenting diagnostic imaging procedure volumes, which is providing a fillip to the market.

Competitive strategies, such as acquisitions and indication extensions for existent products, adopted by players are expected to trigger the growth of the market. The companies stirring changes in the space is restricted to few in number. Among these, Guerbet, GE Healthcare, and Bayer were the forerunners with top-selling drugs in their respective portfolios and commanding more than 40% share in 2016. Bayer holds a prominent position in the arena owing to its leading MRI agent, Gadavist/Gadovist, a macrocyclic gadolinium agent. Guerbet is giving a stiff competition to its contemporaries since it has joined forces with Mallinckrodt. The acquisition has led to a streamlined portfolio of MRI and x-ray/CT contrast materials, which now hold center position in this space. GE competes with Omnipaque and Visipaque as a part of its suite of offerings, which account for nearly 12.0% market share.




Along with increasing incidence of chronic diseases, rising demand and use of diagnostic imaging modalities is driven by advancements in the underlying technologies. Equipment advancements include innovation such as syringeless injectors, which help in achieving greater accuracy in dose delivery, shorter examination time, and higher patient throughput.
Regionally, North America will continue to dominate the contrast media agents market throughout the forecast period. Presence of well-established healthcare infrastructure, availability of advanced technologies as well as recent launch of new contrast media agents for specific indications are contributing to the growth of the region.

Browse full research report on Contrast Media Agent Market: www.grandviewresearch.com/industry-analysis/contrast-media-contrast-agents-market    
                         
Further key findings from the study suggest:   
                  
  • In 2016, iodinated contrast agents registered the highest sales in the market due to high penetration of contrast media agents in x-ray and CT procedures, driven by availability of non-ionic stable iodinated agents for improved diagnosis
  • X-ray/CT modality technique led the market in terms of revenue in 2016 due to its wide acceptance and utilization in the market
  • Gastrointestinal applications are anticipated to register the fastest growth over the forecast period due to regulatory approval of new products in the U.S. market. For instance, Tagitol V was recently approved by the U.S. FDA for use in adult patients undergoing CTC procedures
  • On the regional front, North America captured the highest revenue in 2016 owing to presence of well-established healthcare infrastructure and availability of advanced technologies
  • Europe was the second largest segment in 2016, attributable to increasing usage of diagnostic imaging modalities such as MRI, CT, and ultrasound in the region
  • Key players in this space are Bayer AG, GE Healthcare, Guerbet, Lantheus Medical Imaging, and Bracco Diagnostics
  • Most of the key players are focusing on entering untapped regions and expanding their product portfolios through mergers and acquisitions.

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                                                                                                                                  
Grand View Research has segmented the global contrast media agents market on the basis of agent type, modality, application, and region:

Contrast Media Agents Type Outlook (Revenue, USD Billion, 2016 - 2025)
  • Iodinated contrast media
  • Barium-based contrast media
  • Gadolinium-based contrast media
  • Microbubble contrast media
Contrast Media Agents Modality Outlook (Revenue, USD Billion, 2016 - 2025)
  • X-ray/CT contrast agents
  • MRI contrast agents
  • Ultrasound contrast agents
Contrast Media Agents Application Outlook (Revenue, USD Billion, 2016 - 2025)
  • Cardiovascular disorders
  • Neurological disorders
  • Gastrointestinal disorders
  • Cancer
  • Nephrological disorders
  • Musculoskeletal disorders
  • Others
Contrast Media Agents Regional Outlook (Revenue, USD Billion, 2016 - 2025)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • France
  • Asia
    • Japan
    • India
  • Row
Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-contrast-media-contrast-agents-market                                                                                                                                                    
About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Epigenetics Market to Observe Strong Development by 2022

The global  epigenetics market  is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.  Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is expected to attract pharmaceutical companies to collaborate for the development of therapeutic drugs.  Presence of pipeline drugs and their expected commercialization is anticipated to boost penetration rates over the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.  Technology advancements in the field of epigenetics especially pertaining to t
Read more

Increasing Incidences Of M&A Of CDMO/CRO With Big Pharma Companies To Drive Life Sciences BPO Market Growth Till 2024: Grand View Research, Inc.

Image
The  life sciences BPO market  is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.  The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.  North America life sciences BPO market, by services, 2013 - 2024 (USD Billion) In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth
Read more

U.S. Telehealth Market Is To Be $2.83 Billion By 2022: Grand View Research, Inc.

Image
U.S. telehealth market  is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research Inc. Increasing access to basic healthcare is the major aim of telehealth along with improved healthcare quality and patient safety by early detection and diagnosis. According to a report published by the Agency for Health Care Research and Quality (AHRQ), implementation of telehealth solution improves quality of care delivery to patients.  The rising demand for self care and independent living along with the concept of home care is highly appealing to the population. The Rhode Island Partnership for Home Care reported that in 2014, over 20,000 citizens demanded for home care that led to approximately 1,000,000 visits by healthcare providers. Advantages that drive the higher adoption for home care include better psychological impact on patients, provision of friendly environment, care provision as per patient needs, and cost-effectiveness.  U.S. telehealth
Read more